Treatment of a mixed acinar-endocrine carcinoma with uptake on 68Gallium-DOTATOC positron emission tomography-computed tomography : a case report [PDF]
, 2017 The case of a 35-year old female patient with a diagnosis of metastatic mixed acinar-endocrine carcinoma (MAEC) is investigated in the present study.
De Both, Anneleen +5 more
core +2 more sources
RADIONUCLIDE IMAGING AND THERAPY OF NEUROENDOCRINE TUMOURS
Journal of Cancer and Allied Specialties, 2015 The incidence and prevalence of neuroendocrine tumours (NETs) are on the rise. Although NETs are a heterogeneous group of tumours, they have some similar properties, for example, that they can concentrate neuroamines and tend to have a high degree of ...
Shaunak Navalkissoor +1 more
doaj +1 more source
Preclinical efficacy of hK2 targeted [177Lu]hu11B6 for prostate cancer theranostics [PDF]
, 2019 Androgen ablating drugs increase life expectancy in men with metastatic prostate cancer, but resistance inevitably develops. In a majority of these recurrent tumors, the androgen axis is reactivated in the form of increased androgen receptor (AR ...
Beattie, Bradley J. +10 more
core +2 more sources
New Developments in Peptide Receptor Radionuclide Therapy [PDF]
Journal of Nuclear Medicine, 2018 Peptide Receptor Radionuclide Therapy (PRRT) is an established treatment for non-operable or metastatic neuroendocrine neoplasms that express highly and frequently somatostatin receptors. More generally, PRRT is an attractive therapy option for delivering cytotoxic radiation to tumor cells through specific binding of a radiolabeled peptide to a ...
Nicolas GP +3 more
openaire +3 more sources
Peptide Receptor Radionuclide Therapy – Prospects for Personalised Treatment [PDF]
Clinical Oncology, 2021 Peptide receptor radionuclide therapy is a type of molecular radiotherapy that has been used in the treatment of patients with neuroendocrine tumours for over two decades. It is not until recently, however, that it has achieved regulatory approval. The currently approved treatment regimen is a one-size-fits-all scheme, i.e. all patients receive a fixed
A, Sundlöv, K, Sjögreen-Gleisner
openaire +2 more sources
Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future [PDF]
, 2019 In recent decades, the incidence of neuroendocrine tumors (NETs) has steadily increased. Due to the slow-growing nature of these tumors and the lack of early symptoms, most cases are diagnosed at advanced stages, when curative treatment options are no ...
Amthauer, Holger +8 more
core +1 more source
Therapeutic sequences in patients with grade 1−2 neuroendocrine tumors (NET): an observational multicenter study from the ELIOS group [PDF]
, 2019 Purpose: Many different treatments are suggested by guidelines to treat grade 1−2 (G1−G2) neuroendocrine tumors (NET). However, a precise therapeutic algorithm has not yet been established.
Badalamenti, G. +17 more
core +1 more source
Peptide Receptor Radionuclide Therapy versus Capecitabine/Temozolomide for the Treatment of Metastatic Pancreatic Neuroendocrine Tumors. [PDF]
Cancers (Basel)Gujarathi R +4 more
europepmc +3 more sources
Targeted radiotherapy of neuroblastoma: future directions [PDF]
, 2017 No abstract ...
Gaze, Mark N. +4 more
core +2 more sources
Pharmaceuticals, 2019 As the first radiopharmaceutical for Peptide Receptor Radionuclide Therapy (PRRT), Lutathera® was approved by the EMA in 2017 and the FDA in 2018 for the treatment of somatostatin receptor (SSTR) positive gastroenteropancreatic neuroendocrine tumors.
Ute Hennrich, Klaus Kopka
doaj +1 more source